Cart
sales@molnova.com
XE-991
CAS No. 122955-42-4
XE-991( XE991 )
Catalog No. M10901 CAS No. 122955-42-4
XE-991 is a potent, selective and orally active blocker of voltage-gated potassium channels Kv7 (KCNQ) that blocks KCNQ1, KCNQ2 and KCNQ2+KCNQ3 with Kd of 0.78, 0.7 and 0.6 uM, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 87 | In Stock |
|
| 5MG | 79 | In Stock |
|
| 10MG | 126 | In Stock |
|
| 25MG | 242 | In Stock |
|
| 50MG | 403 | In Stock |
|
| 100MG | 603 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameXE-991
-
NoteResearch use only, not for human use.
-
Brief DescriptionXE-991 is a potent, selective and orally active blocker of voltage-gated potassium channels Kv7 (KCNQ) that blocks KCNQ1, KCNQ2 and KCNQ2+KCNQ3 with Kd of 0.78, 0.7 and 0.6 uM, respectively.
-
DescriptionXE-991 is a potent, selective and orally active blocker of voltage-gated potassium channels Kv7 (KCNQ) that blocks KCNQ1, KCNQ2 and KCNQ2+KCNQ3 with Kd of 0.78, 0.7 and 0.6 uM, respectively; displays 14-fold less potency for KCNQ1+minK current with Kd of 11 uM, enhances hippocampal ACh release from rat brain slices (EC50=490 nM) and is a cognitive enhancer in vivo.Alzheimer Disease Discontinued.
-
In VitroXE 991 dihydrochloride possesses an EC50 of 490 nM for enhancement of [3H]ACh release from rat brain slices, and shows good in vivo potency and duration of action.
-
In Vivo——
-
SynonymsXE991
-
PathwayCell Cycle/DNA Damage
-
TargetPotassium Channel
-
RecptorPotassium Channel
-
Research AreaNeurological Disease
-
IndicationAlzheimer Disease
Chemical Information
-
CAS Number122955-42-4
-
Formula Weight376.45
-
Molecular FormulaC26H20N2O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC1=CC=C2C(=C1)C(=O)C3=CC=CC=C3C2(CC4=CC=NC=C4)CC5=CC=NC=C5.Cl.Cl
-
Chemical Name10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Zaczek R, et al. J Pharmacol Exp Ther. 1998 May;285(2):724-30.
2. Wang HS, et al. Mol Pharmacol. 2000 Jun;57(6):1218-23.
3. MacVinish LJ, et al. Mol Pharmacol. 2001 Oct;60(4):753-60.
4. Yeung SY, et al. Br J Pharmacol. 2005 Oct;146(4):585-95.
molnova catalog
related products
-
Tolazamide
Tolazamide is an oral blood glucose lowering drug used for people with Type 2 diabetes.
-
XE 991 dihydrochlori...
A potent, selective and orally active blocker of voltage-gated potassium channels Kv7 (KCNQ) that blocks KCNQ1, KCNQ2 and KCNQ2+KCNQ3 with Kd of 0.78, 0.7 and 0.6 uM, respectively.
-
QO-40
QO-40 is a KCNQ2/3 potassium channels activator.QO-40 potently augmented KCNQ2/3 channels expressed in Chinese hamster ovary cells and shifted the half-maximal activation voltage (V(1/2)) in the hyperpolarizing direction.?The V(1/2) was negatively shifted in a concentration-dependent manner.?
